Impact of Perioperative Physical Activity on Postoperative Pulmonary Complications and Quality of Life Among Esophageal Cancer Patients
Impact of Perioperative Physical Activity on Postoperative Pulmonary Complications and Quality of Life Among Esophageal Cancer Patients: A Prospective Cohort Study
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Young Mog Shim, MD
- Phone Number: +82-2-3410-6491
- Email: genehee.lee@samsung.com
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Samsung Medical Center
-
Contact:
- Jae Kyung Lee, MSc
- Phone Number: +82-2-3410-6491
- Email: jk1230.lee@sbri.co.kr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who are diagnosed with esophageal cancer and scheduled to receive curative esophagectomy
- Patients who are able to read and understand the questionnaire
- Patients who are able to communicate with research personnel
- Patients who recognize the purpose of this study and provide written informed consent
- Patients without treatment for psychiatric disease
Exclusion Criteria:
- Patients who have difficulty for walking
- Patients with history of other cancer in the last 3 years
- Patients with neoadjuvant chemotherapy and/or radiation therapy
- Patients with recurrent esophageal cancer
- Patients with multiple cancer
- Foreigner or overseas patients who were not able to regularly participate this study
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pulmonary complications
Time Frame: Within 30 days after surgery
|
Incidence of pneumonia and atelectasis
|
Within 30 days after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change of quality of life
Time Frame: Before surgery(baseline), and 1, 6, 12, 24, 36, 48, and 60 months after surgery
|
The change of quality of life is measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) core30 (C30).
The quality of life scale is transformed into a score 0 to 100, derived by 4-point Likert scale.
A higher score represents a higher level of quality of life.
|
Before surgery(baseline), and 1, 6, 12, 24, 36, 48, and 60 months after surgery
|
|
The change of symptom
Time Frame: Before surgery(baseline), and 1, 6, 12, 24, 36, 48, and 60 months after surgery
|
The change of symptoms is measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) oesophageal cancer module (OES18).
The symptom scale is transformed into a score 0 to 100, derived by 4-point Likert scale.
A higher score represents a higher level of symptom.
|
Before surgery(baseline), and 1, 6, 12, 24, 36, 48, and 60 months after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Young Mog Shim, MD, Samsung Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2014-10-035
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Neoplasms
-
NCT02392377TerminatedStage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal Adenocarcinoma | Stage IIB Esophageal Adenocarcinoma | Stage IB Esophageal Adenocarcinoma | Stage IIA Esophageal Adenocarcinoma
-
NCT07416825CompletedEsophageal Cancer | Esophageal Carcinoma
-
NCT06745193Not yet recruiting
-
NCT07309991RecruitingEsophageal Adenocarcinoma | Esophageal Carcinoma | Esophagectomy | PaO2 | Esophageal Anastomotic Leakeage
-
NCT01927016CompletedEsophageal Neoplasm | Esophageal Disease
-
NCT00570531TerminatedLoco-regional Esophageal Cancer
-
NCT01269970CompletedEsophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)
-
NCT01490749CompletedEsophageal Cancer | Neoplasms, Esophageal
-
NCT03708042Not yet recruitingStage III Esophageal Cancer | Stage II Esophageal Cancer
-
NCT02959385UnknownStage III Esophageal Cancer | Stage II Esophageal Cancer